GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses

  title={GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses},
  author={Sean D. Donevan and Michael A. Rogawski},

Figures and Tables from this paper

Negative allosteric modulation of AMPA-preferring receptors by the selective isomer GYKI 53784 (LY303070), a specific non-competitive AMPA antagonist.
GYKI 53784 is the most potent of the compounds in the 2,3-benzodiazepine class, blocking AMPA receptor-mediated responses, and may be of potential clinical value, both in acute (stroke and trauma) and chronic neurological disorders.
Regulation of glutamate release by presynaptic kainate receptors in the hippocampus
Kainate elicits a dose-dependent decrease in L-glutamate release from rat hippocampal synaptosomes and also depresses glutamatergic synaptic transmission, indicating that glutamate release can be modulated directly by kainate autoreceptors.
BIIR 561 CL: a novel combined antagonist of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors and voltage-dependent sodium channels with anticonvulsive and neuroprotective properties.
Data show that BIIR 561 CL is a combined antagonist of AMPA receptors and voltage-gated sodium channels with promising anticonvulsive and neuroprotective properties.
Interactions of 2,3‐benzodiazepines and cydothiazide at AMPA receptors: patch clamp recordings in cultured neurones and area CA1 in hippocampal slices
1 The 2,3‐benzodiazepines GYKI 52466, GYKI 53405 and GYKI 53655 antagonized AMPA‐induced currents in cultured superior colliculus neurones in a non use‐dependent manner (steady state IC50S: GYKI
Effects of the non‐NMDA antagonists NBQX and the 2,3‐benzodiazepine GYKI 52466 on different seizure types in mice: comparison with diazepam and interactions with flumazenil
The data indicate that the GABAA receptor‐associated benzodiazepine site is not critically involved in anticonvulsant or adverse effects of GYKI 52466, and demonstrates that non‐NMDA antagonists lack a selective anticonVulsant action in standard models of generalized seizures.


The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466, in mice
Arcaine blocks N-methyl-D-aspartate receptor responses by an open channel mechanism: whole-cell and single-channel recording studies in cultured hippocampal neurons.
Results indicate that arcaine inhibits NMDA-induced [3H]dizocilpine binding by blocking the open NMDA receptor channel, an action that is independent of the polyamine site.
Electrophysiological studies with a 2,3-benzodiazepine muscle relaxant: GYKI 52466.
N-methyl-D-aspartate antagonists prevent kainate neurotoxicity in rat retinal ganglion cells in vitro
Findings indicate that the KA-induced portion of retinal ganglion cell death also appears to be mediated via NMDA receptors, consistent with the hypothesis that KA adds an increment of toxicity in this system by directly interacting with KA receptors.
Non-NMDA receptor-mediated neurotoxicity in cortical culture
Quisqualate-induced late neuronal degeneration may be due to another unexpected process: cellular quisqualates uptake and delayed release, converting brief addition into prolonged exposure, and high concentrations of quisQualate may directly activate NMDA receptors or induce the release of endogenous glutamate.
Quinoxalinediones as excitatory amino acid antagonists in the vertebrate central nervous system.
Quinoxalinediones: potent competitive non-NMDA glutamate receptor antagonists.
Quinoxalinediones have been found to be potent and competitive antagonists at non-NMDA glutamate receptors and will be useful in the determination of the structure-activity relations of quisqualate and kainate receptors and the role of such receptors in synaptic transmission in the mammalian brain.